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biodiversity and the existence of nature. Human ma-
lignancies consist of cellular sub-populations with
various pathological features and biological
characteristics.
Intratumor heterogeneity includes differences in the
histology, antigenicity, immunity, hormone receptors,
metabolism, gene changes, growth rate, and the re-
actions to drugs.1 Presently, there are at least two
models that describe the heterogeneity of tumors. The
first model, intratumor heterogeneity in evolutionary
models of tumor progression, refers to the heteroge-
neity of the phenotypes and proliferation ability of the
tumor cell population that originated from one single
cell. Malignant transformation of the cells involves
multiple steps including the initial mutation, latency,
tumor promotion, and progression, which occurs after* Corresponding author. Tel.: þ86 010 85231768; fax: þ86 10
88324270.
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have been considered to be the basis of the heteroge-
neity of the tumor cells, while diversities of the ge-
notypes and phenotypes are the basis of tumor
heterogeneity. However, studies have also shown that
genetic mutation may not necessarily lead to changes
of the phenotypes of the cells.2 The second model is
called the ‘tumor stem cell model’. Tumor stem cells
have the ability to self-renew and undergo multi-
directional differentiations which are the basis of het-
erogeneity.2,3 Currently, the molecular basis of intra-
tumor heterogeneity has already been confirmed in
multiple tumors including breast cancer, malignant
glioma, pancreatic cancer, and leukemia.4 Gyneco-
logical tumors also consist of cellular sub-populations
with different pathological features and biological
characteristics; in other words, intratumor heteroge-
neity also exists in gynecological tumors.1,5 While the
knowledge about intratumor heterogeneity has pro-
gressed greatly with the advance of related studies, the
clinical significance of intratumor heterogeneity in the
diagnosis, treatment, and follow-up of malignant tu-
mors are still uncertain. In the present study, the clin-
ical significance of intratumor heterogeneity in the
diagnosis, treatment, and follow-up of gynecological
tumors were reviewed.Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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significance in the pathological diagnosis of
gynecological tumors
Recent advances in the development of new tech-
niques in molecular biology research have created op-
portunities to improve the diagnosis of tumors, which
include immunohistochemical staining, chromosome
banding technique, fluorescence in situ hybridization,
comparative genomic hybridization (CGH),6 array CGH,
tiling CGH, single nucleotide polymorphism, and next
generation sequencing.7 Especially important are single
cell amplification methods8 and molecular profiling of
single circulating tumor cells with diagnostic intention.9
There are studies that have investigated the intratumor
heterogeneity not only at the morphological level of the
tumor cells, but also at the level of DNA, RNA, and
protein, which will have importance for providing indi-
vidualized treatments and deciding treatment strategies.
In clinical practice, pathological diagnosis has been
accepted as the gold standard for developing treatment
strategies for malignant tumors. In addition, correct
pathological diagnosis is also of significance for the
prognosis of the patients. The morphologies of the tu-
mors are generally very similar when observed under the
microscope; however, there are no two tumors with
exactly identical gene expression at the molecular level.
Hence, conventional pathological diagnosis of tumor
could result in several deviations in guiding the treatment
selection; specifically in cases of pathological diagnosis
on the basis of single biopsy findings with limited
available information, treatment selection can be inap-
propriate.10 In the studies of tissues obtained from pri-
mary breast cancers and their metastases, Rao et al11 and
Yao et al12 found that therewere heterogeneities between
the primary breast cancer and their metastatic tumors.
Ting et al5 investigated the polycomb group (PcG) pro-
teins from the tissues of recurrent epithelial ovarian
cancers and found significant differences in the expres-
sion between the primary cancer tissues and the recurrent
cancer tissues. These findings suggest that there is het-
erogeneity between the recurrent tumors and the primary
tumors. Due to the existence of intratumor heterogeneity,
multiple specimens from different sites of the tumor are
necessary for the pathological diagnosis in clinical
practice. Additionally, the size of the specimens should
also be considered, and genetic examinations should be
performed if necessary to detect the changes of the
intratumor heterogeneity, which would guide the choice
of treatment strategies for the patients with metastatic
tumors or recurrent tumors, provide individualized
treatment, and improve the prognosis of the patients.Furthermore, because of the existence of intratumor
heterogeneity, the pathological diagnoses in the future
should include the combination of conventional and mo-
lecular pathological classifications, which could ensure
that clinicians attain accurate diagnosis and individual-
ized treatment for the patients with tumors. TheAmerican
College of Medical Genetics Cytogenetics Resource
Committee discussed the intratumor heterogeneity of the
human epidermal growth factor receptor (HER) 2 gene in
breast cancer, and standardized the diagnostic criteria of
the genetic heterogeneity of theHER1 gene in detail. This
helped to choose individualized Trastuzumab treatments
for the patients with breast cancer.13,14
Significances of intratumor heterogeneity in the
clinical treatments of malignant gynecological
tumors
Most of the patients with advanced tumors are prone
to develop chemotherapy resistance during clinical
treatment for malignant gynecological tumors, which
results in treatment failure and a poor prognosis. There
are multiple mechanisms involved in chemotherapy
resistance which are associated with the growth and
repair of the tumor cells, intratumor genetic heteroge-
neity, and heterogeneity in cell growth.
Under normal conditions, the DNA repair mechanism
is a very important function to ensure the stability of the
cells; however, potent DNA repair function can also
rapidly repair theDNAdamage in the tumor cells induced
by the chemotherapy, and thus induce the resistance to
chemotherapy.15 The intratumor genetic heterogeneity,
functional heterogeneity, and growth time heterogeneity
of the tumor cells may also induce chemotherapy resis-
tance in the cells.16,17 Specifically, the effects of the
intratumor genetic heterogeneity on molecular targeted
therapy can result in chemotherapy resistance.18,19 In
addition, genetic mutations may also occur after the
chemotherapy, which could further induce the alterations
in the phenotypes followed by chemotherapy resistance
of the tumors.20 Hence, the intratumor genetic heteroge-
neity and cell growth heterogeneity should be considered
when selecting the appropriate individualized treatment
strategies to avoid the development of drug resistance.
Recently, sequential chemotherapy was developed
based on the Norton-Simon hypothesis. In sequential
chemotherapy, non-cross-resistant drugs are used
sequentially. In brief, drug A at an appropriate dose is
administered for several cycles followed by drug B at an
appropriate dose for several cycles. In sequential
chemotherapy, a single drug or combination of drugs
could be used to target tumor cells with different
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effectiveness of chemotherapy and to reduce the drug-
related adverse reactions.21,22 Theoretically, using
sequential chemotherapy could overcome the difficulties
caused by the intratumor heterogeneity, and thus it could
provide a better treatment strategy. Presently, sequential
chemotherapy is being used in the treatment of high-risk
trophoblastic tumors, breast cancers, and lung cancers,
and it has shown better effectiveness compared with
conventional combined chemotherapy.
The National Comprehensive Cancer Network of
the United States of America guidelines issued in 2014
recommended a combined chemotherapy of paclitaxel
and platinum as a first-line treatment strategy for
epithelial ovarian cancer,23 and 6e8 cycles of
chemotherapy for the patients with advanced tumors.
However, as there is intertumor heterogeneity among
different types of epithelial ovarian cancers, the
response of individual types of tumors to chemo-
therapy can be different. In addition, intratumor het-
erogeneity also exists within the same type of ovarian
carcinoma. Hence, sequential chemotherapy as the
first-line treatment strategy is more rational for the
treatment of epithelial ovarian cancers.
In a phase II clinical trial, compared the effectiveness
and safety of sequential chemotherapy of gemcitabine
plus oxaliplatin and carboplatin plus Taxol in 18 patients
with stage III/IV ovarian cancer. The study results
showed that the complete remission rate was 92.0%, and
the toxic reactions induced by the chemotherapy were
all acceptable.24 In the Potamianou et al25 study, 52
patients with ovarian cancer were treated with sequen-
tial chemotherapy of carboplatin plus Taxol or Taxol
liposomes plus Adriamycin. The overall chemotherapy
reaction rate was 66%, among which the complete
remission rate was 44% and the partial remission rate
was 22%.The toxic reactions induced by the chemo-
therapy were also acceptable. Li et al26 performed a
clinical study in 41 patients with epithelial ovarian
cancer, and it was found that sequential chemotherapy
could improve the progression-free survival (PFS) and
reduce the side-effects compared with a conventional
chemotherapy group. The findings of these studies
suggest that sequential chemotherapy could improve the
survival and life quality of the patients with ovarian
tumors, especially when molecular targeted therapy is
used in combination with chemotherapy. However, as
most of the studies that investigated the application of
sequential chemotherapy in treating epithelial ovarian
cancers were with relatively small sample sizes, more
multi-center clinical studies are needed to further
identify the best sequential therapy strategy.Significances of intratumor heterogeneity in the
clinical treatment and follow-up of the patients
with malignant gynecological tumors
In light of the intratumor heterogeneity, the hetero-
geneities in the genotypes and phenotypes of the tumor
sub-clone could change after chemotherapy. Li et al27
investigated the tumor biomarkers in the serum after
chemotherapy of patients with epithelial ovarian cancers
and found that the spectrum of the tumor biomarkers
changed during the chemotherapy and in the recurrent
tumors; in addition, the changes of the types of bio-
markers were associatedwith the resistance of the tumors
and the prognosis of the patients. The study results sug-
gested the existence of intratumor heterogeneity. More-
over, it also suggested that during the treatment and
follow-up, the traditional tumor biomarker monitoring
strategy should be changed; the biomarkers that were
normal before the treatment should also be monitored in
addition to the abnormally expressed tumor biomarkers,
which might help to identify the abnormal changes
occurred in these biomarkers after chemotherapy. This
could help to detect the tumor recurrence early andmight
help to adjust the treatment strategy accordingly.
Ting et al5 investigated the PcG proteins in the
tissues from primary and recurrent epithelial ovarian
cancers and found that these proteins were expressed
significantly differently between the primary tumors
and the recurrent tumors. The expression of B cell-
specific Moloney murine leukemia virus integration
site 1 and the enhancer of zeste 2 polycomb repressive
complex 2 subunit, the two members of the PcG pro-
teins family in the primary and recurrent tumors, could
help to predict the differences in the PFS and overall
survival of the patients. These findings suggested that
there was intratumor heterogeneity in the recurrent and
metastatic tumors, which were associated with the
prognosis of the patients. In another study, Gerlinger
et al.28 performed exome sequencing, chromosome
aberration analysis, copy-number analysis, immuno-
histochemical staining, mutation function analysis, and
messenger RNA expression examinations in primary
and metastatic renal cancers. The results showed the
molecular base of the intratumor heterogeneity.
Moreover, it was identified that the intratumor het-
erogeneity could affect the response to chemotherapy
as well as the clinical outcome of the patients. Gulati S
et al29 performed a further study to systemically
investigate the intratumor heterogeneity and the prog-
nostic biomarkers in patients with renal cancer, and the
results also showed that the intratumor heterogeneity
was associated with the clinical prognosis of the
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significance of intratumor heterogeneity in the clinical
prognosis of the patients should be performed.
In summary, there is intertumor heterogeneity and
intratumor heterogeneity. The major goals of gyneco-
logical oncology should include an accurate determi-
nation and effective control of tumor heterogeneity and
thereby improve the diagnosis, therapeutic strategies,
and follow-up of patients and produce an improved
quality of life and survival.
During clinical pathological diagnosis, pay attention
to the representative biopsy materials and the puncture
multi-point sampling. Serum tumor marker expression in
patients with epithelial ovarian carcinoma may change
after chemotherapy or recurrence, indicating that in
addition to the markers that are abnormal before surgery,
those markers that are normal should also be monitored
during chemotherapy and follow-up. Sequential
chemotherapy and individualized treatment strategies
are recommended for first-line chemotherapy in patients
with epithelial ovarian carcinoma to improve the curative
effect and the quality of life, and to decrease the drug
resistance and adverse effects.References
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